Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

At the 40th J.P. Morgan Healthcare Conference, Moderna Inc (NASDAQ: MRNA) said it expects FY21 product sales of approximately $17.5 billion.

Moderna At Annual J.P. Morgan Healthcare Conference, Inks Oncology Pact With Carisma Therapeutics

Pfizer

Pfizer and Moderna are utilizing the same mRNA technology found in Covid-19 vaccines to try to develop a one-time universal flu cure.

A universal flu vaccine may be the next big mRNA breakthrough for Moderna, Pfizer

Moderna CEO Stephane Bancel said the omicron specific booster will enter clinical trials soon.

Moderna's working with world health leaders on Covid booster that targets omicron for this fall, CEO says

Moderna Inc said on Monday it expected to record sales of about $18.5 billion in 2022 from contracts for its COVID-19 vaccines, about $3.5 billion for potential additional purchases including booster candidates updated for variants.

Moderna raises 2022 vaccine sales forecast to $18.5 billion

807 million doses of Moderna's COVID-19 vaccine shipped globally in 2021; approximately 25% of those doses shipped to low- and middle-income countries Product sales for 2021 approximately $17.5 billion (unaudited) Increasing APAs for 2022 delivery to approximately $18.5 billion and approximately $3.5 billion in options Announcing a new collaboration with Carisma Therapeutics for in vivo chimeric antigen receptor monocyte (CAR-M) therapeutics for the treatment of cancer, including solid tumors Company continues to scale with 40 programs in development, including 23 in ongoing clinical studies CAMBRIDGE, MA / ACCESSWIRE / January 10, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced recent updates on its industry-leading mRNA pipeline. Moderna continues to scale, now with 40 programs in development including 23 in ongoing clinical studies encompassing mRNA infectious disease vaccines and mRNA therapeutics spanning seven different modalities.

Moderna Announces Advances Across Its Industry-Leading mRNA Pipeline and Provides Business Update

Collaboration will combine Carisma's engineered macrophage technology with Moderna's mRNA and LNP technologies to generate and develop in vivo CAR-M therapeutics Multi-year research collaboration funded by Moderna with options for up to twelve targets Carisma to receive $45 million up-front cash payment and investment by Moderna in the form of a $35 million convertible note Carisma eligible to receive milestone and royalty payments CAMBRIDGE, MA and PHILADELPHIA, PA / ACCESSWIRE / January 10, 2022 / Moderna Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Carisma Therapeutics Inc., a biopharmaceutical pioneer in engineered macrophage-based therapeutics, today announced that the two companies have entered into a strategic collaboration agreement to discover, develop and commercialize in vivo engineered chimeric antigen receptor monocyte (CAR-M) therapeutics for the treatment of cancer. "We are excited to begin this collaboration with Carisma to further expand our oncology pipeline with a differentiated in vivo cell-therapy approach," said Stephen Hoge, President of Moderna.

Moderna and Carisma Establish Collaboration to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology

This question could make or break the stock in the years ahead.

1 Big Question Facing Moderna in 2022

The Supreme Court seems to be leaning toward striking down a federal vaccine mandate for large businesses.

Why Moderna Stock Was Sluggish on Friday

The shortened waiting period for boosters comes as data shows that two doses do not provide strong protection against symptomatic infection from omicron.

FDA shortens Moderna booster waiting period to 5 months for adults

The move comes days after the agency also shortened the period between the primary Pfizer series and a booster dose to five months.

FDA Cuts Moderna Booster Waiting Period From Six Months To Five

The Food and Drug Administration said Friday that adults who have been vaccinated with Moderna Inc.'s MRNA, -1.05% COVID-19 vaccine can get a booster dose five months after completing the primary series of shots. The previous recommendation was to wait six months.

FDA says adults can now get Moderna's COVID-19 booster five months after getting the first two shots

Investors seem to be increasingly pessimistic about future demand for Moderna's COVID-19 vaccine.

Why Moderna Stock Is Dropping This Week

Moderna Inc.'s CEO expects fully vaccinated people to need an additional COVID-19 booster shot later this year, as the efficacy of the first booster wanes over time.

Moderna CEO expects a second COVID booster will be needed later this year

Moderna CEO Stephane Bancel on Thursday said the efficacy of boosters against Covid-19 will likely decline over time, and people may need a fourth shot in the fall of 2022 to increase their protection.

Moderna CEO says people may need fourth Covid shot as efficacy of boosters likely to decline over time

Moderna (MRNA) doses the first participant in a phase I study evaluating its Epstein-Barr virus vaccine candidate, mRNA-1189.

Moderna (MRNA) Begins Dosing in Study on Vaccine Against EBV

The COVID-19 pandemic is becoming prolonged leading to more deaths and new variants. The company should generate higher net income and revenue in 2022, supporting a stronger net cash position after buybacks.

Moderna Is Growing With The Vaccine Income

Shares of Moderna Inc. MRNA, -0.85% were down 0.5% in premarket trading on Wednesday after the company said it began dosing participants in a Phase 1 clinical trial evaluating the company's experimental Epstein-Barr virus vaccine. The virus causes mononucleosis, also called mono, and is associated with a higher risk of multiple sclerosis and some lymphoproliferative disorders.

Moderna begins Phase 1 study of its Epstein-Barr virus vaccine candidate

Moderna expects to enroll approximately 270 participants in the U.S. EBV is a major cause of infectious mononucleosis, which can debilitate patients for weeks to months; there is no approved vaccine to prevent EBV EBV can also lead to lifelong medical conditions and is associated with an increased risk of developing multiple sclerosis, certain lymphoproliferative disorders, cancers, and autoimmune diseases Moderna now has a portfolio of two vaccines against latent viruses in the clinic: CMV and EBV CAMBRIDGE, MA / ACCESSWIRE / January 5, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the first participant has been dosed in the Phase 1 study of mRNA-1189, the Company's Epstein-Barr Virus (EBV) vaccine candidate. The study is known as Eclipse.

Moderna Announces First Participant Dosed in Phase 1 Study of its mRNA Epstein-Barr Virus (EBV) Vaccine

After dropping from record highs in August 2021, now may be a good time to assess Moderna's long-term value.

Is Now a Good Time to Buy Moderna Stock?

CAMBRIDGE, MA / ACCESSWIRE/ January 4, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that CEO Stéphane Bancel will participate in a fireside chat at the Goldman Sachs 14th Annual Healthcare CEOs Unscripted Conference on Thursday, January 6th at 2:00 p.m. ET. A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com.

Moderna to Present at the Goldman Sachs 14th Annual Healthcare CEOs Unscripted Conference

News that Moderna Inc. ( MRNA , Financial) had shipped about 800 million doses of its Covid-19 vaccine to more than 60 countries in 2021 -- and more than tripled the amount of cash and cash equivalents it held – caught Wall Street's eye on Tuesday morning.

Moderna Injects Analysts, Investors With Confidence

Tesla

The winners on the first trading day of 2021 mostly went on to outperform the S&P 500. The losers did not.

Tesla and Moderna Started 2022 Very Differently. What History Says Happens Next.

Moderna stock had a banner year of sorts in 2021, as the company quickly scaled up production and distribution of its Covid-19 shot. Moderna's financial performance has also been great, with sales likely to grow over 13x year-over-year to more than $17 billion for 2021, with profits likely.

Should You Buy Moderna Stock At $250?

Moderna Inc. MRNA, -7.45% said in a letter to shareholders disclosed Tuesday, Chief Executive Stéphane Bancel said the biotechnology company had shipped about 800 million doses of its COVID-19 vaccine to more than 60 countries in 2021, and more than tripled the amount of cash and cash equivalents it held. Meanwhile, the stock dropped 1.2% in premarket trading, after dropping 7.5% on Monday, and tumbling 27.9% in December.

Moderna shipped 800 million COVID vaccines last year, more than tripled its cash position but stock falls again

Novavax

Both of these coronavirus vaccine innovators have plenty of upside in 2022.

News for Moderna Stock (MRNA)